Preferred Label : Autologous Anti-TIM-3/Anti-CD123 CAR T-cells;
NCIt synonyms : Autologous Anti-Tim3/CD123 CAR-T Cells; anti-TIM-3/anti-CD123 CAR-T cells; Autologous Anti-TIM-3/Anti-CD123 CAR-T Cells; Autologous Anti-CD123/TIM-3 CAR-T Cells;
NCIt definition : A preparation of autologous T-cells engineered to express a chimeric antigen receptor
(CAR) specific for the tumor-associated antigen (TAA) CD123 (interleukin-3 receptor
alpha chain; IL3RA) and the inhibitory T-cell receptor T-cell immunoglobulin and mucin
domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2),
with potential immunostimulating and antineoplastic activities. Upon administration,
the autologous anti-TIM-3/anti-CD123 CAR T-cells target and bind to both CD123 and
TIM-3 that are both expressed on the surface of leukemic stem cells (LSCs) in acute
myeloid leukemia (AML). This induces selective toxicity in CD123- and TIM-3-expressing
LSCs. CD123, the alpha subunit of the IL-3 receptor, regulates the proliferation,
survival and differentiation of hematopoietic cells. TIM-3, a transmembrane protein
and immune checkpoint receptor, is associated with tumor-mediated immune suppression.
TIM-3 has a higher specificity for LSC than CD123, whose expression is not limited
to cancer cells. TIM-3 is not expressed on normal hematopoietic stem progenitor cells
(HSCP), granulocytes, and macrophages. Targeting both TIM-3 and CD123 may reduce the
on-target off-tumor effect and improve efficacy.;
NCI Metathesaurus CUI : CL1926429;
Origin ID : C204172;
UMLS CUI : C5909622;
Semantic type(s)
- chemical_or_drug_affects_cell_type_or_tissue
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- has_target
